NuvoBio Corporation
$30,000.00 CAD
≈ 5 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2025-2026
- Agreement period
- September 1, 2025 – March 31, 2026
- Reference
- nrc-cnrc:172-2025-2026-Q2-1034846
Published purpose
Pre-clinical proof-of-concept studies to assess therapeutic activity in an mRNA-LNP Delivered SMYD3 Peptide Therapeutic both patient-derived cell lines and a murine xenograft model of SCLC. Conduct in vitro screening (viability, proliferation, and apoptosis assays), and in vivo xenograft monitoring. Collect and analyze experimental data; contribute to technical reports and data summaries for internal review and patent support.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions